Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis
Reversion of in vivo fibrogenesis by novel chromone scaffolds - eBioMedicine
Potential mechanisms for the suppression of fibrogenesis by... | Download Scientific Diagram
Renoprotective mechanisms of pirfenidone in hypertension-induced renal injury: through anti-fibrotic and anti-oxidative stress pathways. | Semantic Scholar
Key interactors in the predicted mechanism of action of pirfenidone and... | Download Scientific Diagram
August | 2017 | SugarCone Biotech
A NEW ERA in IPF: Trials and Treatments - ppt download
Guidelines for the Medical Treatment of Idiopathic Pulmonary Fibrosis | Archivos de Bronconeumología
Frontiers | Rationale for the Use of Pirfenidone in Heart Failure With Preserved Ejection Fraction | Cardiovascular Medicine
Pirfenidone | Nature Reviews Drug Discovery
Pirfenidone is a cardioprotective drug: Mechanisms of action and preclinical evidence - ScienceDirect
Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evid | CE
IJMS | Free Full-Text | Idiopathic Pulmonary Fibrosis: Pathogenesis and the Emerging Role of Long Non-Coding RNAs | HTML
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis | European Respiratory Society
Proposed mechanism of action of nintedanib in idiopathic pulmonary... | Download Scientific Diagram
Pirfenidone inhibits epithelial-mesenchymal transition and pulmonary fibrosis in the rat silicosis model - ScienceDirect
吡非尼酮 | New Drug Approvals
Pirfenidone is a cardioprotective drug: Mechanisms of action and preclinical evidence - ScienceDirect
Antifibrotic activities of pirfenidone in animal models | European Respiratory Society
Pirfenidone targets. Different targets in vivo and in vitro for PFD... | Download Scientific Diagram
Treatment for IPF: The changing landscape - ppt download
Pirfenidone: A novel hypothetical treatment for COVID-19. - Abstract - Europe PMC
Frontiers | Rationale for the Use of Pirfenidone in Heart Failure With Preserved Ejection Fraction | Cardiovascular Medicine
Treatment | Idiopathic Pulmonary Fibrosis | Medthority.com
Pirfenidone anti-fibrotic effects are partially mediated by the inhibition of MUC1 bioactivation | Oncotarget
